Vistagen Therapeutics, Inc.

As of June 30, 2026, Vistagen Therapeutics, Inc. carries a market capitalization of 160.03M, placing it among publicly traded companies globally. Its enterprise value stands at -380.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vistagen Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Vistagen Therapeutics, Inc. has 41.03M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.38, and the price-to-book ratio stands at 0.37.

As of June 30, 2026, Vistagen Therapeutics, Inc. maintains a current ratio of 3.07, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. posted a negative return on equity (ROE) of -166.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -129.22, reflecting losses generated across the asset base. The company generates approximately 892,121.29 in revenue per employee across its workforce of 49.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. recorded 122,301.20 in income tax expense. The company reported a pretax loss of -1.18B and -1.18B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Vistagen Therapeutics, Inc. generated 43.71M in revenue and converted that into -1.18B in net income, yielding earnings per share of -31.20. EBITDA reached -1.20B, while operating income came in at -1.22B.

As of June 30, 2026, Vistagen Therapeutics, Inc. holds 554.37M in cash and equivalents against 13.68M in total debt, resulting in a net debt position of -296.86M. Total book value stands at 427.72M, with working capital of 403.91M providing operational flexibility.

Vistagen Therapeutics, Inc. produced -1.09B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.50M in capital expenditures, free cash flow totaled -1.09B - equivalent to -28.78 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -2,784.33 and net profit margin of -2,702.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -738.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -331.82, meaning Vistagen Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Vistagen Therapeutics, Inc.'s most recent stock split took place on June 7, 2023 with a 30:1 split ratio.

As of June 30, 2026, Vistagen Therapeutics, Inc. has an Altman Z-Score of -24.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.